SCHEMBL25840830

SCHEMBL25840830

COc1cc(-c2nccs2)c(-c2ccc3c(N)cnnc3c2)cc1B(O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 14/20 0.41
SMPD3 Q9NY59 1/20 0.37
DHFR P00374 3/20 0.35
SCN9A Q15858 1/20 0.34
JAK2 O60674 1/20 0.34
LCK P06239 1/20 0.34
CSF1R P07333 1/20 0.34
LYN P07948 1/20 0.34
RET P07949 1/20 0.34
IGF1R P08069 1/20 0.34
PDGFRB P09619 1/20 0.34
FGR P09769 1/20 0.34
KIT P10721 1/20 0.34
FGFR1 P11362 1/20 0.34
SRC P12931 1/20 0.34
PDGFRA P16234 1/20 0.34
FGFR2 P21802 1/20 0.34
FGFR4 P22455 1/20 0.34
FGFR3 P22607 1/20 0.34
KIF5B P33176 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL25300128 0.96 PDE10A (0.38) PDE10ASMPD3DHFRSCN9AJAK2
SCHEMBL26067398 0.94 PDE10A (0.39) PDE10ASMPD3DHFRSCN9AJAK2
SCHEMBL25262002 0.90 PDE10A (0.36) PDE10ASMPD3DHFRSCN9AJAK2
SCHEMBL25840901 0.87 LRRK2 (0.33) PDE10ADHFR
SCHEMBL25841373 0.85 PDE10A (0.41) PDE10ADHFR
SCHEMBL25840846 0.85 PDE10A (0.41) PDE10ADHFR
SCHEMBL25840911 0.85 PDE10A (0.41) PDE10ADHFR
SCHEMBL25356388 0.84 PDE10A (0.40) PDE10ADHFR
SCHEMBL26067417 0.84 LRRK2 (0.33) PDE10ADHFR
Formic Acid SCHEMBL25299075 0.83 LRRK2 (0.33) DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
WO-2023137166-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. (US) 2023-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PDE10A 1950/4885SMPD3 80/4885DHFR 1380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.